Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.

Translating preclinical studies to effective treatment protocols and identifying specific therapeutic responses in individuals with cancer is challenging. This may arise due to the complex genetic makeup of tumor cells and the impact of their multifaceted tumor microenvironment on drug response. To find new clinically relevant drug combinations for colorectal cancer (CRC), we prioritized the top five synergistic combinations from a large in vitro screen for ex vivo testing on 29 freshly resected human CRC tumors and found that only the combination of mitogen-activated protein kinase kinase (MEK) and proto-oncogene tyrosine-protein kinase Src (Src) inhibition was effective when tested ex vivo.

Dynamic Ga-PSMA-11 PET/CT for the Primary Evaluation of Localized Renal Mass: A Prospective Study.

The potential role of prostate-specific membrane antigen (PSMA) PET/CT in non-prostate cancer tumors has shown promising results. We examined the performance of dynamic Ga-PSMA-11 PET/CT (DPSMA) for the evaluation of localized renal mass. A prospective case series of patients with a newly diagnosed renal mass who were referred for surgery was examined.

Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.

Objective: To assess patient adherence to intravesical instillation therapy for nonmuscle invasive urothelial carcinoma outside of clinical trials.

Materials And Methods: We reviewed the records of patients from 2000 to 2013 who received intravesical therapy for nonmuscle invasive urothelial carcinoma. Patients with evidence of tumor recurrence or progression were excluded.

Diagnostic Needle Biopsies in Renal Masses: Patient and Physician Perspectives.

Background: The utility of renal mass biopsies (RMB) in the diagnosis of kidney tumors remains debatable.

Objective: To assess patient and urologist preferences regarding the utilization of RMB.

Design, Setting, And Participants: Seventy-three patients diagnosed with renal tumors and 59 board-certified urologists were asked to participate in an interview-based study.